According to Shanwaishan's announcement, net profit attributable to owners of the parent company for the first three quarters of 2026 is estimated to be 151 million yuan to 167 million yuan, up 44.23% to 59.41% in the same period last year; deducted non-net profit is estimated to be 137 million yuan to 151 million yuan, and 94.0868 million yuan for the same period last year, up 45.17% to 60.45% year on year. The change in performance was mainly due to the increase in product market share, which led to an increase in sales revenue of blood purification equipment, a sharp increase in sales revenue from self-produced consumables, and an increase in gross margin.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.